research use only

Ponatinib hydrochloride Bcr-Abl inhibitor

Name: Ponatinib hydrochloride
Brand: Selleck Chemicals
SKU: E7000
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E7000

Ponatinib hydrochloride is a potent, orally available multi-targeted inhibitor of Pan BCR-ABL kinase. It potently inhibits ABL with an IC50 of 0.37 nM, also inhibits SRC , VEGFR2, FGFR1, PDGFRα, LYN with an IC50s of 5.4 nM, 1.5 nM, 2.2 nM, 1.1 nM, 0.24 nM respectively and exhibits significant potential in cancer reserach.

Chemical Structure

Molecular Weight: 569.02

Jump to

Quality Control

Batch: E700001 DMSO]25 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.89%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.89

Related Targets	EGFR VEGFR FGFR PDGFR c-Met Src MEK CSF-1R FLT3 HER2
Other Bcr-Abl Inhibitors	Degrasyn (WP1130) Bafetinib (INNO-406) Rebastinib (DCC-2036) GNF-5 Berbamine GNF-2 Olverembatinib dimesylate (GZD824) PD173955 GNF-7 Berbamine dihydrochloride

Solubility

In vitro
Batch:

DMSO : 25 mg/mL (43.93 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.25mg/ml (2.20mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.15mg/ml (0.26mM)	Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	569.02	Formula	C₂₉H₂₇F₃N₆O.ClH	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1114544-31-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/19878872/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-02-10)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06860269	RECRUITING	Acute Lymphoblastic Leukemia	Assistance Publique - Hôpitaux de Paris	2025-05-06	PHASE2; PHASE3
NCT01746836	RECRUITING	Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive	M.D. Anderson Cancer Center	2013-01-17	PHASE2
NCT07614022	NOT_YET_RECRUITING	Philadelphia Positive Acute Lymphoblastic Leukemia	Wake Forest University Health Sciences	2026-10	PHASE1
NCT06061094	RECRUITING	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	Goethe University	2023-07-14	PHASE2
NCT04070443	ACTIVE_NOT_RECRUITING	Philadelphia Chromosome Positive CML; BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	2019-11-13	PHASE2
NCT06514534	RECRUITING	Chronic Myeloid Leukemia (CML)	Novartis Pharmaceuticals	2025-02-18	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):